John H Saunders1,2, Christopher R Bowman1, Alex M Reece-Smith1, Vincent Pang2, Matthew S Dorrington2, Errum Mumtaz1, Irshad Soomro3, Philip Kaye3, Srinivasan Madhusudan4, Simon L Parsons1,2. 1. Department of Upper GI Surgery, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 2. Cancer Biology Unit, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom. 3. Department of Histopathology, Nottingham University Hospitals NHS Trust, Nottingham, United Kingdom. 4. Academic Unit of Oncology, Division of Cancer and Stem Cells, School of Medicine, University of Nottingham, Nottingham, United Kingdom.
Abstract
BACKGROUND AND OBJECTIVES: For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response. It is unclear whether those with no neoadjuvant chemotherapy response should go onto receive adjuvant chemotherapy, as no further benefit may be conferred. METHODS: Esophagogastric cancers were prospectively captured with associated histopathological tumor regression grades following neoadjuvant chemotherapy. This cohort was then interrogated for clinico-pathological and survival outcomes. RESULTS: Following neoadjuvant chemotherapy and surgery, patients with chemotherapy responsive cancers, who were administered adjuvant chemotherapy gained a significant overall survival benefit. Multivariate Cox analysis, demonstrated a final adjusted hazard ratio for adjuvant therapy of 0.509; (95%CI 0.28-0.93); P = 0.028. In contrast, patients with non-responsive tumors, who underwent adjuvant chemotherapy, did not show any survival benefit. Chemotherapy toxicity was prevalent and contributed to only half of patients receiving adjuvant chemotherapy. CONCLUSIONS: These results suggest the benefit of the adjuvant portion of chemotherapy is limited to those who demonstrate a histopathological response to neoadjuvant chemotherapy. The administration of the adjuvant portion of chemotherapy to patients without a response to neoadjuvant chemotherapy may not provide any survival benefit, while potentially causing increased morbidity.
BACKGROUND AND OBJECTIVES: For patients with operable esophagogastric cancer, peri-operative chemotherapy confers a significant overall survival benefit compared to surgery alone, however only 30-40% of patients demonstrate histopathological response. It is unclear whether those with no neoadjuvant chemotherapy response should go onto receive adjuvant chemotherapy, as no further benefit may be conferred. METHODS: Esophagogastric cancers were prospectively captured with associated histopathological tumor regression grades following neoadjuvant chemotherapy. This cohort was then interrogated for clinico-pathological and survival outcomes. RESULTS: Following neoadjuvant chemotherapy and surgery, patients with chemotherapy responsive cancers, who were administered adjuvant chemotherapy gained a significant overall survival benefit. Multivariate Cox analysis, demonstrated a final adjusted hazard ratio for adjuvant therapy of 0.509; (95%CI 0.28-0.93); P = 0.028. In contrast, patients with non-responsive tumors, who underwent adjuvant chemotherapy, did not show any survival benefit. Chemotherapy toxicity was prevalent and contributed to only half of patients receiving adjuvant chemotherapy. CONCLUSIONS: These results suggest the benefit of the adjuvant portion of chemotherapy is limited to those who demonstrate a histopathological response to neoadjuvant chemotherapy. The administration of the adjuvant portion of chemotherapy to patients without a response to neoadjuvant chemotherapy may not provide any survival benefit, while potentially causing increased morbidity.
Authors: Yanshuo Cao; Qing Chang; Michael Cabanero; Wenjiang Zhang; Sara Hafezi-Bakhtiari; David Hedley; Gail Darling; Fayez Quereshy; Raymond Jang; Elena Elimova; Jennifer Knox; Olga Ornatsky; Stefano Serra; Eric Chen Journal: J Gastrointest Cancer Date: 2019-12
Authors: F Noble; M A Lloyd; R Turkington; E Griffiths; M O'Donovan; J R O'Neill; S Mercer; S L Parsons; R C Fitzgerald; T J Underwood Journal: Br J Surg Date: 2017-09-25 Impact factor: 6.939
Authors: Astrid E Slagter; Marieke A Vollebergh; Edwin P M Jansen; Johanna W van Sandick; Annemieke Cats; Nicole C T van Grieken; Marcel Verheij Journal: Front Oncol Date: 2020-11-30 Impact factor: 6.244
Authors: W R C Knight; J Zylstra; M Van Hemelrijck; N Griffin; A E T Jacques; N Maisey; C R Baker; J A Gossage; J Largergren; A R Davies Journal: BJS Open Date: 2018-03-15